The identification of peptide masses plays a critical role in the area of protein and glycoprotein analysis in two main ways: Peptide Mass Fingerprinting (PMF) and Peptide Mapping. Each of these techniques relies on peptide mass identification but work in subtly different ways with different applications in protein structural investigations. We will look at the merits of each of these techniques in this article.
Firstly, Peptide Mass Fingerprinting (PMF), also known as protein fingerprinting, is a proteomic technique used as part of modern protein identification strategies. It works by comparing the masses of a protein’s digested peptide fragments, along with any generated fragment ions, to known protein databases. This approach is a powerful and efficient method widely used in biopharmaceutical research to confirm protein identity.
Peptide Mass Fingerprinting is a powerful tool for protein identification, able to provide protein identity from very small amounts of material, such as is typically used in gel electrophoresis. Thus, unknown bands on gels can be identified. Low level impurities from LC preparations can also be identified in this way, providing useful information on sample composition which can serve to support manufacturing process control.
It also has application in Host Cell Protein (HCP) identification and quantitation. HCP investigations are important for the assessment of protein impurities in a product and are required by regulatory authorities as part of impurity profiling of biopharmaceutical products. The mass spectrometric analysis of HCPs offers some advantages over ELISA-based methods and is seen as complimentary. The use of MS and ELISA methods provides more information than either technique alone can provide. In this case Peptide Mass Fingerprinting is performed on the whole sample to ensure no loss of HCPs from a purification process.
Peptide Mapping is a very powerful analytical tool that has a number of similarities to Peptide Mass Fingerprinting but with significant differences in terms of application. In this instance the protein identity is known, with Peptide Mapping being used to identify key structural features of the protein and provide information such as:
Analysis of various proteolytic digests is carried out via on-line LC/ESI-MS to provide a profile of the peptide species produced along with mass data of each component, allowing confirmation of anticipated structure or identification of potential post-translational modifications.
Peptide Mapping is critical in protein and glycoprotein analysis and is vital part of the structural characterization required for getting these classes of drugs to market.
Peptide Mapping can detect post-translational modifications such as oxidation, deamidation, phosphorylation, and glycosylation as well as a wide range of other post-translational modifications that may affect the function, stability, or immunogenicity of therapeutic proteins. Knowledge of the type and extent of post translational modifications of a molecule is necessary not just for the required full investigation of protein structure but also serves to provide information on the manufacturing process itself – information which can then be fed back for process improvement.
In biosimilar development, Peptide Mapping is an essential tool for comparing the primary amino acid structure of a biosimilar candidate to its originator. The biosimilar must be 100% identical to the innovator in terms of primary amino acid sequence for any claim of biosimilarity to stand. This is a key requirement in demonstrating biosimilarity under EMA, FDA and MHRA guidelines.
Peptide Mapping is also used to monitor lot-to-lot consistency during biomanufacturing. Any sequence truncations, unexpected cleavages, or alterations to PTM profiles can be quickly flagged through changes in the peptide mass profile. This is especially useful during process changes, scale-up, or technology transfer.
Regulatory bodies (such as the EMA, FDA and MHRA) expect applicants to demonstrate that therapeutic proteins are well-characterized. Peptide Mapping data contributes directly to ICH Q6B compliance by verifying identity, structure, and batch comparability. It can also be used to support stability studies and forced degradation studies.
Have a peptide program that needs analytical support? Get in touch and we'll help you design the right characterization strategy.
Peptide mapping is one piece of a larger analytical picture. Download our white paper for a complete guide to structural characterization strategies for peptide therapeutics.
Our scientists have decades of experience in protein characterization allowing BioPharmaSpec to be a trusted partner to biopharmaceutical companies worldwide. Our experts bring industry insight and regulatory expertise to every project, ensuring your data stands up to scrutiny.
We use high-resolution mass spectrometers, including Q-TOF, Triple Quad, and MALDI-TOF, to deliver reliable Peptide Mass Fingerprinting and Peptide Mapping results. These workflows are aligned with ICH guidelines and are proven in regulatory submissions for monoclonal antibodies, biosimilars, and recombinant proteins.
What sets us apart is our hands-on approach. Clients work directly with experienced scientists who help interpret results and customise analytical strategies. Whether you're developing a new biologic or verifying an existing product, we provide the clarity and confidence you need to move forward.
Peptide Mass Fingerprinting and Peptide Mapping are both powerful, efficient, and necessary techniques for protein identification and characterization.
At BioPharmaSpec, we offer more than just analytical services, but insight into what the data generated mean for you and your product. Our scientists work with you to design and execute strategies aligned with your molecule and regulatory goals.
Looking for confidence in your protein analytical needs? Speak to a Scientist and see how we can help.
